Copyright
©The Author(s) 2023.
World J Gastroenterol. Nov 7, 2023; 29(41): 5683-5698
Published online Nov 7, 2023. doi: 10.3748/wjg.v29.i41.5683
Published online Nov 7, 2023. doi: 10.3748/wjg.v29.i41.5683
Figure 5 Verification the tumorigenic ability of CBC2T-2 cells in non-obese diabetic/severe combined immunodeficient mice.
A: Tumor formation in non-obese diabetic/severe combined immunodeficient mice; B: Body weight gain curves in xenograft mice; C: Tumor size over time in three xenograft mice; D: Hematoxylin and eosin staining and immunohistochemical (CK19, CD68, CD117, Vmention, Desmin) results of primary tumors, CBC2T-2 xenografts and CBC2T-2. Scale bars, 50 and 100 μm. HE: Hematoxylin and eosin.
- Citation: Jiang NZ, Bai MZ, Huang CF, Ma ZL, Zhong RY, Fu WK, Gao L, Tian L, Mi NN, Ma HD, Lu YW, Zhang ZA, Zhao JY, Yu HY, Zhang BP, Zhang XZ, Ren YX, Zhang C, Zhang Y, Yue P, Lin YY, Meng WB. First report on establishment and characterization of the extrahepatic cholangiocarcinoma sarcoma cell line CBC2T-2. World J Gastroenterol 2023; 29(41): 5683-5698
- URL: https://www.wjgnet.com/1007-9327/full/v29/i41/5683.htm
- DOI: https://dx.doi.org/10.3748/wjg.v29.i41.5683